Prolight: SpinChip deal highlights the strategic importance and valuation potential of Prolight's solution - Emergers

The recent acquisition of Norwegian point-of-care diagnostics platform SpinChip by bioMérieux for EUR 138 million underscores the growing interest, strategic importance and value potential of rapid in-vitro diagnostics. SpinChip’s acquisition value reflects a full takeover, which involves a higher risk for the buyer than licensing-in a technology, which is the path we base our fair value estimate of Prolight on. But applying a takeover scenario to our numbers would support a value of USD 150m, translating to SEK 2.1 per share, suggesting a significant premium to our fair value of SEK 0.9-1.0 per share.

Länk till analysen i sin helhet: https://www.emergers.se/prolight-h/